Regulatory decisions made by the Food and Drug Administration (FDA) often serve as important catalysts for pharmaceutical stocks. In the following video, health-care analyst Max Macaluso discusses three upcoming FDA decisions -- on drugs developed by pharma giant Merck (NYSE: MRK ) , GlaxoSmithKline (NYSE: GSK ) , and needle-free injection pioneer Antares Pharma (NASDAQ: ATRS ) -- and why investors need to keep a close watch on the outcomes of these decisions.
Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, the Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more, click here to claim your copy today.